Metabolic
Pemvidutide
Also called ALT-801
per administration
It has been used in people, but no trial has settled how much or how often.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 1.67mg/mL
- Volume per draw
- 0.72mL
- Units to dial
- 72
- Doses per cartridge
- 4
This is 72 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.
Dial range varies by pen; 1–60 units is the common configuration.
Vial label
Copy this into your label printer.
Published research contexts for Pemvidutide describe 1.2–2.4 mg per administration. Descriptive only, not a recommendation.
Multi-day, consistent with once-weekly administration; precise human figures are not well characterized.
A GLP-1 and glucagon dual receptor agonist studied for weight reduction in phase 1/2 research. No confirmed dose-ranging publication fixes a subcutaneous schedule, so no schedule table is shown.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Pemvidutide (ALT-801) early-phase program (Altimmune)Weekly subcutaneous GLP-1/glucagon dual agonist in early-phase weight research; no dose-ranging trial has fixed a schedule in published form.